Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
16.81
Dollar change
+0.36
Percentage change
2.19
%
Index- P/E- EPS (ttm)-17.57 Insider Own83.68% Shs Outstand85.42M Perf Week-0.83%
Market Cap1.44B Forward P/E- EPS next Y- Insider Trans-0.06% Shs Float13.94M Perf Month-11.57%
Income-44.24M PEG- EPS next Q- Inst Own0.71% Short Float0.87% Perf Quarter-36.23%
Sales0.00M P/S- EPS this Y- Inst Trans-1.39% Short Ratio1.43 Perf Half Y162.45%
Book/sh-11.77 P/B- EPS next Y- ROA-215.90% Short Interest0.12M Perf Year425.39%
Cash/sh0.03 P/C643.91 EPS next 5Y- ROE-269.01% 52W Range3.00 - 30.40 Perf YTD-34.57%
Dividend Est.- P/FCF- EPS past 5Y48.84% ROI-1257.95% 52W High-44.70% Beta2.07
Dividend TTM- Quick Ratio2.88 Sales past 5Y- Gross Margin- 52W Low460.33% ATR (14)1.79
Dividend Ex-DateSep 21, 2022 Current Ratio2.88 EPS Y/Y TTM-411.66% Oper. Margin0.00% RSI (14)48.90 Volatility12.01% 9.58%
Employees- Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom2.00 Target Price45.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q73.25% Payout- Rel Volume0.74 Prev Close16.45
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume84.71K Price16.81
SMA20-1.50% SMA500.38% SMA20030.14% Trades Volume62,603 Change2.19%
Date Action Analyst Rating Change Price Target Change
Apr-29-21Resumed Stephens Overweight $18 → $19
Feb-10-21Initiated Piper Sandler Overweight $15
May-21-20Initiated Raymond James Outperform $20
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Mar-28-24 05:32AM
Mar-26-24 06:32AM
06:00AM
Mar-21-24 07:00AM
Dec-15-23 09:04AM
07:00AM Loading…
Nov-13-23 07:00AM
Oct-30-23 12:00PM
Aug-23-23 12:36PM
Apr-03-23 09:01AM
Mar-29-23 10:13AM
Feb-28-23 08:00AM
Dec-27-22 07:00AM
Nov-16-22 05:05AM
Sep-19-22 09:43AM
Sep-01-22 04:05PM
08:00AM Loading…
Aug-25-22 08:00AM
Aug-23-22 07:11AM
Aug-19-22 08:00AM
Aug-15-22 04:05PM
Aug-11-22 06:00AM
Aug-10-22 12:46PM
Aug-03-22 08:00AM
Aug-01-22 08:30AM
07:30AM
Jul-22-22 12:21PM
Jul-19-22 08:00AM
Jul-14-22 09:40AM
Jul-06-22 08:00AM
Jun-29-22 08:00AM
Jun-28-22 09:40AM
11:03AM Loading…
May-26-22 11:03AM
May-23-22 09:57AM
08:30AM
May-09-22 08:30AM
Apr-08-22 09:57AM
Mar-31-22 08:00AM
Mar-15-22 05:00PM
Feb-17-22 08:00AM
Feb-03-22 05:38PM
Jan-25-22 08:00AM
Jan-12-22 12:00PM
Dec-20-21 07:51PM
Dec-11-21 11:59AM
Nov-22-21 08:00AM
Nov-12-21 09:54AM
09:24AM
07:00AM
Oct-29-21 08:00AM
Oct-28-21 03:05PM
Oct-13-21 04:05PM
Sep-28-21 04:01PM
Sep-24-21 08:00AM
Sep-17-21 07:06AM
Sep-15-21 08:00AM
Sep-09-21 08:00AM
Sep-08-21 08:00AM
Aug-05-21 10:55AM
08:00AM
Jul-29-21 03:05PM
Jul-22-21 08:00AM
Jul-19-21 04:01PM
02:09AM
Jul-14-21 08:00AM
Jul-06-21 08:00AM
Jul-01-21 08:00AM
Jun-28-21 08:45AM
08:00AM
Jun-21-21 06:00AM
Jun-10-21 08:00AM
May-20-21 02:57AM
May-18-21 08:00AM
May-13-21 08:00AM
May-06-21 12:19PM
09:23AM
09:15AM
08:00AM
May-05-21 12:29PM
08:00AM
Apr-28-21 08:00AM
Apr-21-21 11:43AM
Apr-19-21 08:00AM
Apr-12-21 08:00AM
Apr-07-21 04:05PM
Mar-21-21 04:20AM
Mar-04-21 08:00AM
Feb-18-21 08:00AM
Feb-11-21 04:01PM
Feb-10-21 10:05AM
Feb-03-21 08:00AM
Jan-29-21 04:01PM
Jan-27-21 08:00AM
Jan-26-21 04:04PM
Jan-20-21 08:00AM
Jan-19-21 11:46PM
Jan-15-21 08:00AM
Dec-15-20 10:28PM
Dec-07-20 08:00AM
Dec-03-20 04:02PM
08:50AM
Dec-02-20 08:00AM
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
USMAN NASSIMDirectorApr 01 '24Option Exercise6.9320,000138,60021,636Apr 03 04:01 PM
USMAN NASSIMDirectorApr 01 '24Sale16.1520,000323,0001,636Apr 03 04:01 PM
USMAN NASSIMDirectorMar 15 '24Option Exercise6.9320,000138,60021,636Mar 19 04:47 PM
USMAN NASSIMDirectorMar 15 '24Sale17.2620,000345,2001,636Mar 19 04:47 PM